The Main Reason for Adding Progesterone to Estrogen in Perimenopausal Women
The primary reason for administering progesterone to perimenopausal women using estrogen is to decrease the risk of endometrial hyperplasia and endometrial cancer.
The Critical Evidence
The FDA drug label explicitly states that progesterone capsules are "indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens" 1. This is the fundamental, FDA-approved indication.
Multiple high-quality guidelines consistently emphasize this point:
- Unopposed estrogen increases endometrial cancer risk by 2 to 12-fold, with the greatest risk (15- to 24-fold) occurring with prolonged use of 5-10 years or more 1
- Adding progestogen for at least 12 days per month reduces this risk to the level found in never-users of estrogen therapy 2
- The Endocrine Society guideline explicitly states: "concurrent progestogen therapy for at least 12 days per month reduces this risk and is recommended for all women with a uterus" 2
Why the Other Options Are Incorrect
Preventing hot flashes: This is incorrect. Estrogen, not progesterone, is the primary treatment for vasomotor symptoms. Progesterone may have some effect on hot flashes when used as monotherapy 3, but this is not why it's added to estrogen therapy.
Preventing osteoporosis: While estrogen provides bone protection, adding progesterone does not significantly enhance this benefit. The guidelines note that "progestogen has limited effect on the bone-enhancing action of ET" 4. Estrogen alone is responsible for fracture risk reduction 5.
Promoting growth of the uterine lining: This is the opposite of progesterone's role. Progesterone opposes the proliferative effects of estrogen on the endometrium 6. Estrogen stimulates endometrial growth; progesterone counteracts this stimulation to prevent hyperplasia.
Clinical Context and Safety
The U.S. Preventive Services Task Force found "convincing evidence" that unopposed estrogen use increases endometrial cancer risk in women with an intact uterus 5. This is why estrogen-only therapy is restricted to women who have had a hysterectomy.
Key clinical principle: Any woman with a uterus receiving estrogen therapy must receive adequate progestogen protection. The standard regimen is progesterone 200 mg daily for 12-14 days per month sequentially, or continuous combined therapy 7.
Common Pitfall to Avoid
Do not prescribe estrogen alone to any woman with an intact uterus, regardless of how bothersome she finds progestogen side effects. The endometrial cancer risk is substantial and well-documented. If side effects are problematic, adjust the progestogen type, dose, or regimen—but never eliminate endometrial protection 4.